P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

deCODEand Roche Sign Landmark Alliance to Develop Integrated DNA-Based Diagnostic Tools and Related Services and Software

NDReg2

Date: 21 Mar 2008
Time: 08:37:19

Comments

http://www.monstersofcock.com/t1/revs=milfreg/ http://www.bigmouthfuls.com/t1/revs=milfreg/ http://www.firsttimeauditions.com/main.htm?id=chikenn http://www.blackcockswhitesluts.com/?revid=28792 http://www.milfhunter.com/main.htm?id=chikenn http://www.herfirstbigcock.com/?revid=28792 http://www.tugjobs.com/t1/revs=milfreg/ http://www.vipcrew.com/main.htm?id=chikenn

Date: 02 Jul 2001
Time: 12:08:54

Comments

Contacts: deCODE genetics F. Hoffmann-LaRoche Edward Farmer Rolf Schlaepfer +354-570-2819 +41-61688-8888 info@decode.is

Noonan/Russo Communications Ernie Knewitz +1-212-696-4455 ext. 204

The Alliance Has a Total Potential Value to deCODE of Over $300 Million

Reykjavik, ICELAND, July 2 -- deCODE genetics (Nasdaq: DCGN; Nasdaq Europe) today announced that, effective June 29, 2001, it has signed with F. Hoffmann-LaRoche Ltd. AG the definitive terms of their landmark five-year alliance to develop and market DNA-based diagnostics for major diseases. The companies announced the signing of a letter of intent to establish this alliance in March.

The worldwide market for genomic diagnostics is estimated to grow to $4 billion over the next ten years, and Roche aims to build on its global leadership in the field of diagnostics to capture a significant share of this market. Roche's alliance with deCODE is a key component of its long-term strategy. The companies estimate that the total value of the collaboration to deCODE could exceed $300 million.

The alliance is also a central element in deCODE's ongoing strategy of creating value by turning its unique research platform and achievements into products on the market. The alliance builds on key deCODE and Roche assets: deCODE's comprehensive population genomics resources and bioinformatics expertise, and Roche's preeminence in the development and marketing of molecular diagnostics. In addition to the development of novel DNA-based diagnostic and predisposition screening products, the companies hope to develop point-of-care informatics products that can assist doctors in evaluating the results of DNA-based diagnostic tests.

Kari Stefansson, CEO of deCODE genetics, said, "We are very excited to be able to bring together our gene research and bioinformatics know-how with the development and marketing expertise of the world's leading diagnostics company. We believe that these tools and decision-support systems will become a fundamental component of future medicine, and that this alliance will create significant value for deCODE going forward."

deCODE genetics (www.decode.com), based in Reykjavik, Iceland, is conducting research into the inherited causes of common diseases. The company has three main business units: discovery services -- including disease-gene research, drug target identification and pharmacogenomic services; database services; and bioinformatics tools and services. deCODE is using its population approach to turn raw genomics data into products and services for the global healthcare industry.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on strategic partners, ability to obtain financing, competitive products and other risks identified in deCODE's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. deCODE undertakes no obligation to publicly release any revisions to these forward-looking statements resulting from events or circumstances after the date hereof.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName